USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novartis AG

USPTO PatentsView assignee record — 1,768 granted patents across 126 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

1,768
Total patents granted
126
CPC technology areas
15.8
Avg claims per patent
-52%
5-year filing velocity

Portfolio overview

Novartis AG has been granted 1,768 US utility patents between 2015 and 2025, placing Novartis AG at rank #230 across all assignees tracked by PlainPatent. This portfolio spans 126 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Novartis AG is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 63.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 570 grants, compared with 1,198 in the 2015–2019 window — a -52% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Novartis AG's 15.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a diversified footprint across 100+ CPC subclasses spreads risk across many technology fronts. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Novartis AG against peers pursuing similar technology classes.

How does Novartis compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Novartis holds 1,768 patents — placing it at rank #230 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

050100150200250300 20152016201720182019202020212022202320242025 57
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Novartis AG patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 229 13.0%
2016 253 14.3%
2017 270 15.3%
2018 218 12.3%
2019 228 12.9%
2020 131 7.4%
2021 120 6.8%
2022 97 5.5%
2023 72 4.1%
2024 93 5.3%
2025 57 3.2%

Which technologies does Novartis AG patent most?

Top 15 of 126 technology areas

Patent Moat Analysis

Portfolio Volume Strong
Tech Breadth Diversified
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#230

Across all tracked assignees

Innovation Score

63.9 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Novartis AG hold?
Novartis AG holds 1,768 US granted patents filed between 2015 and 2025, spanning 126 technology areas.
What is Novartis AG's Innovation Score?
Novartis AG has an Innovation Score of 63.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Novartis AG focus on?
Novartis AG's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 1,071 patents. The company has filed patents in 126 CPC subclasses total.
Is Novartis AG's patent filing rate increasing or decreasing?
Novartis AG's recent filing velocity is -52% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Novartis AG's patents?
Novartis AG's patents average 15.8 claims each. This falls within the standard range, providing solid legal coverage.
How is the Novartis AG patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope